001     157103
005     20240229123129.0
024 7 _ |a 10.1093/hmg/ddaa147
|2 doi
024 7 _ |a pmid:32657331
|2 pmid
024 7 _ |a 0964-6906
|2 ISSN
024 7 _ |a 1460-2083
|2 ISSN
024 7 _ |a altmetric:85758512
|2 altmetric
037 _ _ |a DKFZ-2020-01394
041 _ _ |a eng
082 _ _ |a 570
100 1 _ |a Sill, Martin
|0 P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b
|b 0
|e First author
|u dkfz
245 _ _ |a Molecular tumor classification using DNA methylome analysis.
260 _ _ |a Oxford
|c 2020
|b Oxford Univ. Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1630414820_30128
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2020 Oct 20;29(R2):R205-R213#EA:B062#LA:B340#
520 _ _ |a Tumor classifiers based on molecular patterns promise to define and reliably classify tumor entities. The high tissue- and cell type-specificity of DNA methylation, as well as its high stability, makes DNA methylation an ideal choice for the development of tumor classifiers. Herein, we review existing tumor classifiers using DNA methylome analysis and will provide an overview on their emerging impact on cancer classification, the detection of novel cancer subentities and patient stratification with a focus on brain tumors, sarcomas and hematopoietic malignancies. Furthermore, we provide an outlook on the enormous potential of DNA methylome analysis to complement classical histopathological and genetic diagnostics, including the emerging field of epigenomic analysis in liquid biopsies.
536 _ _ |a 312 - Functional and structural genomics (POF3-312)
|0 G:(DE-HGF)POF3-312
|c POF3-312
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Plass, Christoph
|0 P:(DE-He78)4301875630bc997edf491c694ae1f8a9
|b 1
|u dkfz
700 1 _ |a Pfister, Stefan M
|0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
|b 2
|u dkfz
700 1 _ |a Lipka, Daniel
|0 P:(DE-He78)c403a040c97f91902a7d31b93859f9fc
|b 3
|e Last author
|u dkfz
773 _ _ |a 10.1093/hmg/ddaa147
|g p. ddaa147
|0 PERI:(DE-600)1474816-2
|n R2
|p R205-R213
|t Human molecular genetics
|v 29
|y 2020
|x 1460-2083
909 C O |p VDB
|o oai:inrepo02.dkfz.de:157103
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)4301875630bc997edf491c694ae1f8a9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)c403a040c97f91902a7d31b93859f9fc
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-312
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Functional and structural genomics
|x 0
914 1 _ |y 2020
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2020-01-11
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2020-01-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2020-01-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
|d 2020-01-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2020-01-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2020-01-11
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
|d 2020-01-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2020-01-11
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
|d 2020-01-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2020-01-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2020-01-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2020-01-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2020-01-11
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b HUM MOL GENET : 2018
|d 2020-01-11
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2020-01-11
920 2 _ |0 I:(DE-He78)B340-20160331
|k B340
|l Translationale Medizinische Onkologie
|x 0
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l B062 Pädiatrische Neuroonkologie
|x 0
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 1
920 1 _ |0 I:(DE-He78)B370-20160331
|k B370
|l Epigenomik
|x 2
920 1 _ |0 I:(DE-He78)B340-20160331
|k B340
|l Translationale Medizinische Onkologie
|x 3
920 0 _ |0 I:(DE-He78)B062-20160331
|k B062
|l B062 Pädiatrische Neuroonkologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a I:(DE-He78)B370-20160331
980 _ _ |a I:(DE-He78)B340-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21